Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH

Despite the emergence of high quality randomized trial data with the use of antithrombotic agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in patients with coronavirus disease 2019 (COVID‐19), questions still remain as to optimal patient selection for these st...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of thrombosis and haemostasis Ročník 20; číslo 10; s. 2226 - 2236
Hlavní autori:	Spyropoulos, Alex C., Connors, Jean M., Douketis, James D., Goldin, Mark, Hunt, Beverley J., Kotila, Taiwo R., Lopes, Renato D., Schulman, Sam, the International Society on Thrombosis and Haemostasis
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Inc 01.10.2022 Elsevier Limited John Wiley and Sons Inc
Predmet:	anticoagulant Anticoagulants - therapeutic use antiplatelet Antiplatelet therapy antithrombotic therapy coronavirus disease 2019 Coronaviruses COVID-19 COVID-19 Drug Treatment Critical care Fibrinolytic Agents - therapeutic use Hemostasis hospitalization Humans Patients Platelet Aggregation Inhibitors - therapeutic use Recommendations and Guidelines severe acute respiratory syndrome coronavirus 2 Thromboembolism Thrombosis Thrombosis - drug therapy Thrombosis - prevention & control Venous Thromboembolism - prevention & control anticoagulant antithrombotic therapy hospitalization severe acute respiratory syndrome coronavirus 2 antiplatelet coronavirus disease 2019
ISSN:	1538-7836, 1538-7933, 1538-7836
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!